Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAngle Regulatory News (AGL)

  • There is currently no data for AGL

Placing

6 Mar 2006 07:02

Angle PLC06 March 2006 For Immediate Release 6 March 2006 ANGLE plc ('ANGLE' or 'the Company') Placing of up to 10,205,288 new Ordinary Shares at 79 pence per share to raise up to £8.1 million ANGLE plc, the venture management and consulting company specialising in thecommercialisation of technology is pleased to announce a conditional Placing ofup to 10,205,288 new Ordinary Shares at 79 pence per share to raise up to £8.1million before expenses. Key Points • The issue of the Placing Shares, assuming maximum subscription, represents an increase of approximately 61 per cent. in the issued share capital of the Company. The Placing Shares, assuming the maximum number of Placing Shares are issued, will represent approximately 37.6 per cent. of the enlarged share capital following the fund raising; • Application will be made to the London Stock Exchange for the Placing Shares to be admitted to trading on AIM. Subject to First Admission, it is expected that dealings in the First Placing Shares will commence on or around 30 March 2006. Subject to Second Admission, it is expected that dealings in the Second Placing Shares will commence on or around 31 March 2006; • The Placing is subject to, inter alia, the approval of Shareholders. An Extraordinary General Meeting has been convened for 29 March 2006; • The Placing Price of 79p represents a discount of approximately 5.4 per cent. to the closing middle market price of an Ordinary Share on 3 March 2006; • The net proceeds of the Placing (approximately £7.4 million) will be utilised to develop the existing Progeny(R) company portfolio and establish new Progeny(R) companies from the pipeline of opportunities under development; • The Placing will be in two tranches to protect the Company's VCT and EIS status; • Collins Stewart is acting as the Company's nominated adviser and broker. Mulier Capital has also been engaged to assist with the fundraising; • Mulier Capital is taking a 2.23% stake in ANGLE through participating in the Placing on its own account, subscribing for 605,749 Placing Shares at the Placing Price; and • In addition, Mulier Capital will apply part of its commission to acquire a further 0.74% stake of the enlarged share capital. Andrew Newland, Chief Executive of ANGLE, said: "We are delighted with the response from investors to this Placing. It isparticularly pleasing that the Placing has been supported by existing and newinstitutional shareholders, together with our staff. The Placing should strengthen our ability to deliver returns from thecommercialisation of intellectual property both from our existing Progeny(R)company portfolio and from new Progeny(R) companies." Dr Erling Refsum, Director of Mulier Capital, said: "We are pleased with the quality of the investors that have participated in thisfund raising. We were also impressed with the value of the existing Progeny(R)companies and the developing pipeline. Novocellus and Geomerics, in particular,have the potential to revolutionise the IVF and games graphics marketsrespectively." For further information ANGLE plc +44 1483 295830Andrew Newland, Chief ExecutiveIan Griffiths, Finance Director Buchanan Communications +44 20 7466 5000Richard Darby, Suzanne Brocks, James Strong, Amy Rajendran Note to editors: About ANGLE Founded in 1994, ANGLE is an international venture management and consultingcompany focusing on the commercialisation of technology and the development oftechnology-based industry. ANGLE creates, develops and advises technologybusinesses on its own behalf and for its clients. ANGLE operates from officesin the UK, the US and the Middle East. ANGLE is listed on AIM (AGL.L); further information can be found atwww.angleplc.com Introduction Background to and Reasons for the Placing As indicated in the interim results for the period ended 31 October 2005, whichwere announced on 24 January 2006, the Company has identified a wide range ofintellectual property (IP) for potential commercialisation via the Progeny(R)process. It is expected that further Progeny(R) companies will be establishedbefore the end of the full financial year on 30 April 2006. The Company has relationships with many research organisations, a number ofwhich have led to discussions about strategic, long-term relationships withANGLE, and the Directors believe that some of these discussions are progressingwell. With the net proceeds of the Placing, the Directors intend to maintain themomentum of the business developing the existing Progeny(R) company portfolioand establishing new Progeny(R) companies from the pipeline of opportunitiesunder development. ANGLE's Progeny(R) process is well defined and ANGLE's business is scaleable.The net proceeds of the Placing should strengthen ANGLE's ability to deliverreturns from the commercialisation of intellectual property both from itsexisting Progeny(R) company portfolio and from new Progeny(R) companies. The Directors believe that raising finance by way of the Placing is the mostappropriate method of funding the Company at the present time. A general offerto Shareholders by way of rights or other pre-emptive issue is not consideredappropriate at this stage of the Company's development given its size, thecurrent shareholder structure and taking into account timing and costconsiderations. Extraordinary General Meeting An Extraordinary General Meeting of the Company is to be held at SurreyTechnology Centre, The Surrey Research Park, Guildford GU2 7YG on 29 March 2006at 11.00 a.m. At this meeting, resolutions will be proposed to: • increase the authorised share capital of the Company from £4,000,000to £5,000,000; • authorise the Directors, for the purposes of section 80 of the Act, toallot the Placing Shares and the Mulier Capital Subscription Shares and to allowadditional allotments of equity securities equivalent to one-third of theCompany's enlarged share capital following the fund raising; and • disapply statutory pre-emption rights in relation to (a), inter alia,fractional entitlements and to deal with certain overseas securities law issues,(b) the issue of the Placing Shares and the Mulier Capital Subscription Shares,and (c) further issues of Ordinary Shares for cash up to a maximum of 10 percent. of the enlarged share capital following the fund raising. Availability Copies of the placing document are available free of charge from the Company'sregistered office during normal business hours on any weekday (excluding publicholidays) and will remain available for at least one month from the date of thisdocument. Recommendation The Directors of the Company consider the terms of the Placing to be in the bestinterests of the Company and its shareholders as a whole. Accordingly, theDirectors of the Company unanimously recommend Shareholders to vote in favour ofthe Resolutions to be proposed at the Extraordinary General Meeting, as theyintend to do in respect of their own beneficial holdings of Ordinary Sharesamounting, in aggregate, to approximately 44.4 per cent. of the existing issuedshare capital of the Company. This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
5th Dec 20237:00 amRNSANGLE launches Portrait+ CTC kit at SABCS
9th Nov 20237:00 amRNSLaunch of PD-L1 test to support cancer studies
9th Nov 20237:00 amRNSTrading and business update
25th Oct 20237:00 amRNSSupporting characterisation of CTCs in HNSCC
3rd Oct 20237:00 amRNSParsortix outperforms standard for DTC harvest
29th Sep 20237:00 amRNSParsortix system showcased at ACTC conference
7th Sep 20237:00 amRNSInterim Results for the period ended 30 June 2023
4th Sep 20237:00 amRNSANGLE launch of Portrait Flex assay
15th Aug 20237:00 amRNSANGLE notice of interim results
28th Jun 20234:54 pmRNSResult of 2023 Annual General Meeting
27th Jun 202312:24 pmRNSStandard form for notification of major holdings
5th Jun 20237:00 amRNSANGLE announces senior management appointments
25th May 20237:00 amRNSPharma services contract with Artios Pharma
22nd May 20237:00 amRNSBoard change - appointment of new Chairman
21st Apr 202312:04 pmRNSANGLE presentation via Investor Meet Company
21st Apr 20237:00 amRNSResults for the year ended 31 December 2022
19th Apr 20237:00 amRNSANGLE announces partnership with BioView
17th Apr 20237:00 amRNSANGLE Parsortix poster presented at AACR 2023
13th Apr 20237:00 amRNSPharma Services Contract with Crescendo Biologics
3rd Apr 20237:00 amRNSNotice of Preliminary Results and Webcast
10th Mar 20237:00 amRNSIssue of LTIP Options and Share Options
9th Mar 20233:03 pmRNSHolding(s) in Company
9th Feb 20232:44 pmRNSDirector/PDMR shareholding
19th Jan 20237:00 amRNSAppointment of Non-Executive Director
11th Jan 20235:20 pmRNSHolding(s) in Company
10th Jan 20236:20 pmRNSHolding(s) in Company
6th Jan 202311:05 amRNSSecond Price Monitoring Extn
6th Jan 202311:00 amRNSPrice Monitoring Extension
5th Jan 20239:05 amRNSSecond Price Monitoring Extn
5th Jan 20239:00 amRNSPrice Monitoring Extension
5th Jan 20237:01 amRNSAppointment of Non-Executive Director
5th Jan 20237:00 amRNSBusiness Update
12th Dec 20227:00 amRNSTwo Parsortix posters presented at SABCS
2nd Dec 20225:30 pmRNSIssue of Equity
2nd Nov 20227:00 amRNSMultiple downstream analysis techniques for CTCs
1st Nov 20224:41 pmRNSSecond Price Monitoring Extn
1st Nov 20224:35 pmRNSPrice Monitoring Extension
24th Oct 20227:00 amRNSParsortix poster presented at ISLB meeting
21st Oct 20226:15 pmRNSIssue of Equity
18th Oct 20227:00 amRNSStreamlining of operations to increase cash runway
17th Oct 20222:23 pmRNSTR-1: Notification of major holdings
12th Oct 20227:00 amRNSFirst regional distribution agreement
30th Sep 20225:30 pmRNSHolding(s) in Company
30th Sep 20225:30 pmRNSIssue of Equity
29th Sep 20227:00 amRNSInterim Results
29th Sep 20227:00 amRNSPositive headline results from ovarian study
28th Sep 20227:00 amRNSStudy using Parsortix in head and neck cancer
13th Sep 20227:00 amRNSNew poster presented at ASCP Meeting
12th Sep 20227:30 amRNSNovel assay predicts malignancy in pelvic mass
1st Sep 20227:00 amRNSNotice of Interim Results and Webcast

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.